Digirad signs distribution deal with NIR

Article

Digital gamma camera developer Digirad of San Diego announced this month that it has signed a distribution and service agreement with National Imaging Resources for its Digirad 2020 TC Imager. Birmingham, AL-based NIR will gain U.S. distribution rights

Digital gamma camera developer Digirad of San Diego announced this month that it has signed a distribution and service agreement with National Imaging Resources for its Digirad 2020 TC Imager. Birmingham, AL-based NIR will gain U.S. distribution rights to the system, which uses solid-state detectors made from cadmium zinc telluride.

The agreement gives Digirad access to a strong sales structure it has not had before: NIR boasts 190 sales representatives, a 400-member service organization, and a regional network consisting of more than 50 locations. But NIR also expects to benefit from the deal, gaining access to the nuclear medicine market. NIR reports annual sales of more than $500 million.

The deal further strengthens Digirad's market position, especially in light of patents the company received last month that cover a method of manufacturing solid-state digital detector modules (SCAN 10/28/98). Digirad 2020 TC Imager was cleared by the Food and Drug Administration in June 1997 (SCAN 6/11/97).

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.